Featured Image for Q&A

Publications: Ask an Expert about Off-Label Promotion By Sara Dyson, Esq.

Question:  What risk management precautions should a firm take if significant sales are derived from off-label use of its drug or device?

 

Portrait of Author

Sara Dyson, Esq.

Answer: Promoting medical devices and drugs for uses that have not been approved by the Food and Drug Administration (FDA) constitutes off-label promotion, which is forbidden by the Federal Food, Drug and Cosmetic Act (FDCA).  Companies that promote off-label face severe criminal and civil penalties.  In recent years, off-label promotion has been the subject of countless Warning Letters, cost the industry billions in fines, led to jail time for company executives, resulted in Corporate Integrity Agreements and Deferred Prosecution Agreements, and triggered costly products liability lawsuits.  Yet, even so, many medical device and drug companies continue to profit significantly from the off-label uses of their products.

Read more here…

 

 

Food and Drug Administration logo

Food and Drug Administration logo (Photo credit: Wikipedia)

Advertisements

Speak with Speakman...

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s